# Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients

> **NCT06068686** · NA · COMPLETED · sponsor: **Damanhour University** · enrollment: 70 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Vildagliptin 50 MG
- **DRUG:** Glimepiride 3 Mg Oral Tablet

## Key facts

- **NCT ID:** NCT06068686
- **Lead sponsor:** Damanhour University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-01
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-12-01
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06068686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06068686, "Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06068686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*